Overall, our study elucidates the functional role of SHP2 in adaptive resistance to BRAFi in gliomas and highlights the therapeutic potential of combined BRAF and SHP2 inhibition for preventing or overcoming resistance. Here, PTPN11 is linked to central nervous system cancer.